| __timestamp | Alnylam Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50561000 | 24890000000 |
| Thursday, January 1, 2015 | 41097000 | 32639000000 |
| Friday, January 1, 2016 | 47159000 | 30390000000 |
| Sunday, January 1, 2017 | 89912000 | 26107000000 |
| Monday, January 1, 2018 | 74908000 | 22127000000 |
| Tuesday, January 1, 2019 | 219750000 | 22449000000 |
| Wednesday, January 1, 2020 | 492853000 | 24689000000 |
| Friday, January 1, 2021 | 844287000 | 27305000000 |
| Saturday, January 1, 2022 | 1037418000 | 27281000000 |
| Sunday, January 1, 2023 | 1828292000 | 27116000000 |
| Monday, January 1, 2024 | 2248243000 | 28754000000 |
Unlocking the unknown
In the dynamic world of biotechnology, Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc. have carved distinct paths over the past decade. From 2014 to 2023, Gilead Sciences consistently demonstrated robust revenue, peaking in 2015 with a staggering 32.6 billion USD. Despite a slight dip, Gilead maintained an average annual revenue of approximately 26.5 billion USD, underscoring its market dominance.
Conversely, Alnylam Pharmaceuticals, a rising star, showcased an impressive growth trajectory. Starting with a modest 41 million USD in 2015, Alnylam's revenue surged by over 4,300% to reach 1.8 billion USD in 2023. This remarkable growth highlights Alnylam's innovative prowess and strategic market positioning.
As these two companies continue to evolve, their contrasting revenue trends offer valuable insights into the biotech industry's shifting landscape, driven by innovation and strategic foresight.
Revenue Showdown: Bristol-Myers Squibb Company vs Alnylam Pharmaceuticals, Inc.
Revenue Insights: Gilead Sciences, Inc. and BeiGene, Ltd. Performance Compared
Revenue Showdown: Gilead Sciences, Inc. vs Incyte Corporation
Gilead Sciences, Inc. or Catalent, Inc.: Who Leads in Yearly Revenue?
Gilead Sciences, Inc. vs Lantheus Holdings, Inc.: Annual Revenue Growth Compared
Who Generates More Revenue? Gilead Sciences, Inc. or MorphoSys AG
Who Generates More Revenue? Gilead Sciences, Inc. or Bausch Health Companies Inc.
Who Generates More Revenue? Gilead Sciences, Inc. or ImmunityBio, Inc.
Alnylam Pharmaceuticals, Inc. vs Exelixis, Inc.: Examining Key Revenue Metrics
Alnylam Pharmaceuticals, Inc. vs Halozyme Therapeutics, Inc.: Examining Key Revenue Metrics
Breaking Down Revenue Trends: Alnylam Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Alnylam Pharmaceuticals, Inc. and Mesoblast Limited: A Comprehensive Revenue Analysis